⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Recurrence Rate and Esthetic Outcome After Excision of Basal Cell Carcinomas Excluded From Trial NCT00515970

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Recurrence Rate and Esthetic Outcome After Excision of Basal Cell Carcinomas Excluded From Trial NCT00515970

Official Title: Observational Study: Recurrence Rate and Esthetic Outcome After Excision of Basal Cell Carcinomas Excluded From Trial NCT00515970

Study ID: NCT00639652

Study Description

Brief Summary: Currently, we conduct a prospective, randomized trial comparing the outcome of surgical excision with the outcome of curettage in nodular and superficial BCCs. Larger BCCs and micronodular or sclerosing BCCs are not included in the randomized study. They are mainly operated using three-dimensional histology (3D-histology, micrographic surgery). In this observational study we measure the cosmetic result and the recurrence rate of all BCCs not included in the randomized trial.

Detailed Description: 1. Disinfection 2. Local anesthesia 3. Surgery 4. Dressing 5. Preparation with paraffin for histopathologic evaluation 6. Staining with hematoxylin-eosin 7. Adjuvant radiotherapy is not applied in any of our patients. 8. If histopathology discovers another tumor than BCC, the tumor is excluded. 9. If recurrence is suspected, a punch biopsy is taken. If recurrence is confirmed, the endpoint is achieved. 10. Patients who provide no feedback receive phone calls. 11. The patient receives a letter containing a list of the BCCs treated within the study. She or he is asked to visit the private practitioner with the list after 12 and 48 months (+/- 30 days) referring to the last operation in the recruitment period. The practitioner or the patient return the questionnaire to our department. 12. The letter contains a questionnaire about suspicion of recurrence of BCC. 13. The patient is asked to assess the esthetic outcome on a scale of excellent, good, satisfactory, mediocre, and poor. 14. The physician is asked to assess the esthetic outcome on a scale of excellent, good, satisfactory, mediocre, and poor. 15. When follow-up is closed for an individual patient, the reason is recorded: 1. Planned end of follow-up after 48 months 2. Patient has moved. 3. Death (date of death) 4. Consent withdrawn 5. Meanwhile, the patient has become so ill or high-maintenance that no more follow-up visits can be planned. 6. Recurrence of all of the patient's BCCs with histopathologic confirmation.

Eligibility

Minimum Age:

Eligible Ages: CHILD, ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Eberhard Karls University, Department of Dermatology, Tuebingen, , Germany

Contact Details

Name: Helmut Breuninger, M.D.

Affiliation: Eberhard Karls University Tuebingen, Department of Dermatology

Role: STUDY_CHAIR

Name: Kay Brantsch, M.D.

Affiliation: Eberhard Karls University Tuebingen, Department of Dermatology

Role: PRINCIPAL_INVESTIGATOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: